- Home
- STSS vs PRTG Comparison
STSS vs PRTG Comparison
Compare STSS & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- PRTG
- Stock Information
- Founded
- STSS 2017
- PRTG 1973
- Country
- STSS United States
- PRTG British Virgin Islands
- Employees
- STSS N/A
- PRTG N/A
- Industry
- STSS Medical/Dental Instruments
- PRTG Oil & Gas Production
- Sector
- STSS Health Care
- PRTG Energy
- Exchange
- STSS Nasdaq
- PRTG Nasdaq
- Market Cap
- STSS 5.1M
- PRTG 4.7M
- IPO Year
- STSS 2022
- PRTG N/A
- Fundamental
- Price
- STSS $3.47
- PRTG $4.69
- Analyst Decision
- STSS
- PRTG Hold
- Analyst Count
- STSS 0
- PRTG 1
- Target Price
- STSS N/A
- PRTG N/A
- AVG Volume (30 Days)
- STSS 63.4K
- PRTG 40.3K
- Earning Date
- STSS 11-14-2024
- PRTG 12-03-2024
- Dividend Yield
- STSS N/A
- PRTG N/A
- EPS Growth
- STSS N/A
- PRTG N/A
- EPS
- STSS N/A
- PRTG N/A
- Revenue
- STSS N/A
- PRTG N/A
- Revenue This Year
- STSS N/A
- PRTG N/A
- Revenue Next Year
- STSS N/A
- PRTG N/A
- P/E Ratio
- STSS N/A
- PRTG N/A
- Revenue Growth
- STSS N/A
- PRTG N/A
- 52 Week Low
- STSS $2.34
- PRTG $2.10
- 52 Week High
- STSS $18.15
- PRTG $40.80
- Technical
- Relative Strength Index (RSI)
- STSS 60.04
- PRTG 46.17
- Support Level
- STSS $2.54
- PRTG $3.81
- Resistance Level
- STSS $2.99
- PRTG $4.78
- Average True Range (ATR)
- STSS 0.33
- PRTG 0.56
- MACD
- STSS 0.12
- PRTG 0.04
- Stochastic Oscillator
- STSS 81.58
- PRTG 56.33
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes are designed to eliminate potentially infectious and accidental needlestick injuries.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.